PMID- 22261445
OWN - NLM
STAT- MEDLINE
DCOM- 20120306
LR  - 20181201
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 137
IP  - 2
DP  - 2012 Feb
TI  - p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an 
      adverse outcome for patients with relapsed/refractory multiple myeloma treated 
      with lenalidomide.
PG  - 208-12
LID - 10.1309/AJCPHC85DGAXZDBE [doi]
AB  - del(17p13)(TP53) seems to be an independent poor prognostic factor in patients 
      with relapsed/refractory multiple myeloma (MM) receiving lenalidomide. However, 
      whether aberrant p53 nuclear expression detected by immunohistochemical analysis 
      can be used as a surrogate marker for del(17p13)(TP53) in prognostic evaluation 
      of lenalidomide-treated relapsed/refractory MM remains unclear. The p53 
      expression in myeloma cells from 88 patients was evaluated by immunohistochemical 
      analysis, and 17p13(TP53) gene status was examined by fluorescence in situ 
      hybridization (FISH). FISH detected hemizygous del(17p13)(TP53) in 13 (15%), and 
      immunohistochemical analysis detected p53 nuclear expression in 11 cases (13%). 
      del(17p13) (TP53) and p53 expression were strongly correlated (P < .0001). 
      Furthermore, patients with aberrant p53 nuclear expression had significantly 
      shorter progression-free and overall survival than patients without this 
      abnormality. Our results suggest that p53 nuclear expression is associated with 
      adverse outcome in patients with relapsed/refractory MM receiving 
      lenalidomide-based therapy and that p53 immunohistochemical analysis may serve as 
      a simple, rapid method to predict del(17p13)(TP53) in this patient subgroup.
FAU - Chen, Mei-Hsi
AU  - Chen MH
AD  - Dept. of Laboratory Hematology, University Health Network, University of Toronto, 
      200 Elizabeth Street, Toronto, Ontario, Canada.
FAU - Qi, Connie X Y
AU  - Qi CX
FAU - Saha, Manujendra N
AU  - Saha MN
FAU - Chang, Hong
AU  - Chang H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Canada/epidemiology
MH  - Cell Nucleus/*metabolism
MH  - Chromosomes, Human, Pair 17
MH  - DNA, Neoplasm/analysis
MH  - Dexamethasone/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gene Deletion
MH  - Hemizygote
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lenalidomide
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/drug therapy/genetics/metabolism/mortality
MH  - Prognosis
MH  - Recurrence
MH  - Survival Rate
MH  - Thalidomide/*analogs & derivatives/therapeutic use
MH  - *Tumor Suppressor Protein p53/genetics/metabolism
EDAT- 2012/01/21 06:00
MHDA- 2012/03/07 06:00
CRDT- 2012/01/21 06:00
PHST- 2012/01/21 06:00 [entrez]
PHST- 2012/01/21 06:00 [pubmed]
PHST- 2012/03/07 06:00 [medline]
AID - 137/2/208 [pii]
AID - 10.1309/AJCPHC85DGAXZDBE [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2012 Feb;137(2):208-12. doi: 10.1309/AJCPHC85DGAXZDBE.